RVPH
Reviva Pharmaceuticals Holdi
NASDAQ · Pharmaceuticals
$0.29
+0.03 (+12.35%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.36M | 8.56M | 9.00M |
| Net Income | 1.57M | 1.65M | 1.70M |
| EPS | — | — | — |
| Profit Margin | 18.8% | 19.3% | 18.9% |
| Rev Growth | +3.9% | +2.6% | +16.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 5.05M | 5.36M | 5.89M |
| Total Equity | 16.34M | 17.21M | 14.61M |
| D/E Ratio | 0.31 | 0.31 | 0.40 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.64M | 1.79M | 2.00M |
| Free Cash Flow | 1.45M | 1.55M | 1.35M |